BC Week In Review | Sep 5, 2016
Company News

Seikagaku, Ferring deal

Seikagaku granted Ferring exclusive rights outside of Japan to develop and commercialize condoliase ( SI-6603 ), which is in two U.S. Phase III trials to treat sciatica due to lumbar disc herniation. Seikagaku will receive $5...
BC Extra | Aug 29, 2016
Company News

Seikagaku, Ferring in pain deal

Seikagaku Corp. (Tokyo:4548) granted Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) exclusive, worldwide rights to develop and commercialize condoliase ( SI-6603 ), which is in two U.S. Phase III studies to treat sciatica due to lumbar disc herniation....
Items per page:
1 - 2 of 2